127 related articles for article (PubMed ID: 15800893)
1. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
Gadgeel SM; Wozniak A; Boinpally RR; Wiegand R; Heilbrun LK; Jain V; Parchment R; Colevas D; Cohen MB; LoRusso PM
Clin Cancer Res; 2005 Sep; 11(17):6233-9. PubMed ID: 16144926
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
Zhang P; Sun M; Qiu R; Tang L; Dou G; Xu B
Cancer Chemother Pharmacol; 2011 Oct; 68(4):971-8. PubMed ID: 21305287
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Villanueva C; Dufresne A; Pivot X; Viel E
Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]